Exploring an Alternative Preoperative Sentinel Lymph Node Mapping Method Using a Magnetic Tracer and Magnetic Resonance Imaging for Melanoma Patients: SCARLETT Study Protocol
Authors:
- Loeki AldenhovenLALoeki Aldenhoven
- Caroline FrotscherCFCaroline Frotscher
- Rachelle Körver-SteemanRKRachelle Körver-Steeman
- Milou H. MartensMMMilou H. Martens
- Merel A. Spiekerman van WeezelenburgMWMerel A. Spiekerman van Weezelenburg
- Sander M.J. van KuijkSKSander M.J. van Kuijk
- Damir KuburicDKDamir Kuburic
- Alfred JanssenAJAlfred Janssen
- Yvonne L.J. VissersYVYvonne L.J. Vissers
- Elisabeth R.M. van HaarenEHElisabeth R.M. van Haaren
- Patricia QuaedvliegPQPatricia Quaedvlieg
- Geerard L. BeetsGBGeerard L. Beets
Open Access
- 28 November 2025
- journal article
- Published by S. Karger AG in European Surgical Research
- Vol. 67 (1) , 30-37
Abstract
Introduction: Sentinel lymph node biopsy (SLNB) plays a critical role in the clinical management of malignant melanoma. The current standard of care involves the preoperative injection of a Technetium-labeled (99mTc) colloidal nanomaterial to facilitate lymphatic mapping. During surgery, patent blue (PB) is administered to enhance visualization of the lymphatic pathways. However, this dual-tracer approach presents notable drawbacks, including patient exposure to ionizing radiation and logistical challenges stemming from the short half-life of (99mTc). Superparamagnetic iron oxide nanoparticles (SPIO) have emerged as a nonradioactive alternative. Used in conjunction with a handheld magnetometer system (Magtrace® and Sentimag®, Endomagnetics Ltd.), SPIO enables SLN detection without the need for nuclear medicine infrastructure. In clinical studies involving breast cancer patients, SPIO has demonstrated non-inferiority to the conventional 99mTc and PB protocol. Given these findings, SPIO is hypothesized to offer equivalent performance in melanoma patients. This study is designed to evaluate the non-inferiority of preoperative magnetic resonance imaging (MRI) using SPIO compared to traditional lymphoscintigraphy and single-photon emission computed tomography/computed tomography with 99mTc for SLN identification in melanoma. Additionally, the study assesses the non-inferiority of intraoperative SLNB using SPIO and the Sentimag® device relative to the current gold standard based on 99mTc. Methods: A prospective, single-arm, non-inferiority study will be conducted at the Department of Surgical Oncology, Zuyderland Medical Center, Sittard, the Netherlands. The study will enroll 140 adult patients diagnosed with stage I-II primary melanoma who are scheduled to undergo wide local excision and SLNB. All participants will undergo lymphatic mapping using both Magtrace® and 99mTc. The MRI protocol, previously evaluated in a pilot study, was demonstrated to be feasible. Implementation of the MRI protocol will proceed if non-inferiority is established within a predefined margin of 5%. Conclusion: Elimination of radiation exposure is beneficial for both patients and healthcare personnel. Moreover, logistic challenges will be eliminated as SPIO can be injected several days before surgery, immediately followed by MRI scanning. Scheduled surgeries will not be jeopardized by preoperative logistics and procedures. It will increase hospital-oriented productivity, patient-friendliness and comfort as surgical delays are avoided.Keywords
This publication has 19 references indexed in Scilit:
- Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanomaJournal of the American Academy of Dermatology, 2018
- Magnetic Technique for Sentinel Lymph Node Biopsy in Melanoma: The MELAMAG TrialAnnals of Surgical Oncology, 2016
- Superparamagnetic iron oxide as a tracer for sentinel node biopsy in breast cancer: A comparative non-inferiority studyEuropean Journal of Surgical Oncology, 2015
- Comparison of three magnetic nanoparticle tracers for sentinel lymph node biopsy in an in vivo porcine modelInternational Journal of Nanomedicine, 2015
- The Central-European SentiMag study: Sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotopeThe Breast, 2014
- Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in MelanomaNew England Journal of Medicine, 2014
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialThe Lancet Oncology, 2010
- Non‐inferiority tests for clustered matched‐pair dataStatistics in Medicine, 2009
- Is It Necessary to Harvest Additional Lymph Nodes after Resection of the Most Radioactive Sentinel Lymph Node in Breast Cancer?Journal of the American College of Surgeons, 2008
- Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy11No competing interests declared.Journal of the American College of Surgeons, 1999